The Accordance of the Composed of at least five members with varying backgrounds to promote complete and adequate review of research activities commonly conducted by the institution.  The IRB is not composed of at least five members with varying backgrounds to promote complete and adequate review of research in terms of regulations, applicable law and standards of professional conduct and practice. For example:  A. Essex IRB approved a proposed clinical investigator research in terms of regulations, applicable law and standards of professional conduct and practice. For example:  A. Essex IRB approved a proposed clinical investigator of the IRB failed to:  1. Verify that this Clinical Investigator in company who had withdrawn front the market in 2009.  3. Identify that the proposed of protocol was studying an investigational drug previously approved protocol was protocol was previously approved protocol was submitted by the sponsor company who had withdrawn the IND in 2008.  **SEER EVERSE**  **DEFINITION OF THIS PAGE**  **DEFINITION OF THE PAGE**  **DEFINITION OF THIS PAGE**  **DEFINITION OF THIS PAGE**  **DEFINITION OF THE PAGE**  **DEFINITION OF THIS PAGE**  **DEFINITION OF THIS PAGE**  **DEFINITION OF THIS PAGE**  **DEFINITION OF THIS PAGE**  **D			TH AND HUMAN SERVICES		
Parationany. NJ 07054 (973) 331-4900 Fax: (973) 331-4969 Industry Information: www.fda.gov/oc/industry  To: Loretta P. Szczepanski, RN, Essex IRB Vice Chairperson  ***PRINTINGE COMM**  TO: Loretta P. Szczepanski, RN, Essex IRB Vice Chairperson  ***PRINTINGE COMM**  Discount Interpretation of the Pick Review Board, Inc  This document lists observations made by the FDA representatives) during the impection of your facility. They are inspectional observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representatives) during the inspection or submit this information to FDA at the address above. If you have any questions, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representatives) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.  **DURING AN INSPECTION OF YOUR FIRM WE OBSERVED:**  OBSERVATION 1  The IRB is not composed of at least five members with varying backgrounds to promote complete and adequate review of research activities commonly conducted by the institution.  Specifically, Essex IRB failed to demonstrate the ability to ascertain acceptability of the proposed research in terms of regulations, applicable law and standards of professional conduct and practice. For example:  A. Essex IRB approved a proposed clinical investigation (Protocolate) in the initial review, the IRB failed to:  1. Verify that this Clinical Investigator in the initial review, the IRB failed to:  2. Recognize that the Clinical Investigator in the initial review, the IRB failed to:  3. Identify that the proposed protocol was studying an investigational drug that was a previously a	DISTRICT ADDRESS AND PHONE		DATE(S) OF INSPECTION		
PRESENDANCY NO 10034 (973) 331-4969 Industry Information: wow.feda.gov/oc/industry Industry Information: Information: Information Information Information Information: Inform	10 Waterview	Blvd., 3rd Floor			
The Late Late of Loretta P. Szczepanski, RN, Essex IRB Vice Chairperson    Total Loretta P. Szczepanski, RN, Essex IRB Vice Chairperson   Total Loretta P. Szczepanski, RN, Essex IRB Vice Chairperson   Total Loretta P. Szczepanski, RN, Essex IRB Vice Chairperson   Total Loretta P. Szczepanski, RN, Essex IRB Vice Chairperson   Total Loretta P. Szczepanski, RN, Essex IRB Vice Chairperson   Total Loretta P. Szczepanski, RN, Essex IRB Vice Chairperson   Total Loretta P. Szczepanski, RN, Essex IRB Vice Chairperson   Total Loretta P. Szczepanski, RN, Essex IRB Vice Chairperson   Late Loretta P. Szczepanski, RN, Essex IRB Vice Chairperson   Late Loretta P. Szczepanski, RN, Essex IRB Vice Chairperson   Late Loretta P. Szczepanski, RN, Essex IRB Vice Chairperson   Late Loretta P. Szczepanski, RN, Essex IRB Vice Chairperson   Late Loretta P. Szczepanski, RN, Essex IRB Vice Chairperson   Late Loretta P. Szczepanski, RN, Essex IRB Vice Chairperson   Late Loretta P. Szczepanski, RN, Essex IRB Vice Chairperson   Late Loretta P. Szczepanski, RN, Essex IRB Vice Chairperson   Late Loretta P. Szczepanski, RN, Essex IRB Vice Chairperson   Late Loretta P. Szczepanski, RN, Essex IRB Vice Chairperson   Late Loretta P. Szczepanski, RN, Essex IRB Vice Chairperson   Late Loretta P. Szczepanski, RN, Essex IRB Vice Chairperson   Late Loretta P. Szczepanski, RN, Essex IRB Vice Chairperson   Late Loretta P. Szczepanski, RN, Essex IRB Vice Chairperson   Late Loretta P. Szczepanski, RN, Essex IRB Vice Chairperson   Late Loretta P. Szczepanski, RN, Essex IRB Vice Chairperson   Late Loretta P. Szczepanski, RN, Essex IRB Vice Chairperson   Late Loretta Loretta P. Szczepanski, RN, Essex IRB Vice Chairperson   Late Loretta Loretta P. Szczepanski, RN, Essex IRB Vice Chairperson   Late IRB Vice Chairpe	Parsippany, N	J 07054			
This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, and do not represent a final Agency determination or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.  DURING AN INSPECTION OF YOUR FIRM WE OBSERVED:  OBSERVATION 1  The IRB is not composed of at least five members with varying backgrounds to promote complete and adequate review of research activities commonly conducted by the institution.  Specifically, Essex IRB failed to demonstrate the ability to ascertain acceptability of the proposed research in terms of regulations, applicable law and standards of professional conduct and practice. For example:  A. Essex IRB approved a proposed clinical investigation (Protocol for a fictitious sponsor to be conducted by a fictitious clinical investigator for a fictitious sponsor for a fictitious sponsor for a fictitious clinical investigator for a fictitious sponsor for a fictitious sponsor for a fictitious sponsor for a fictitious clinical investigator for a fictitious sponsor for a fictitious sponso	(9/3) 331-490 Industry Info	rmation: www.fda.gov/oc/indu			
This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding you compliance. If you have an objection regarding an observation, and do not represent a final Agency determination regarding you compliance. If you have an objection regarding an observation, and do not represent a final Agency determination regarding you compliance. If you have an objection regarding an observation, and the representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding you compliance. If you have an objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.  **DURING AN INSPECTION OF YOUR FIRM WE OBSERVED:**  **OBSERVATION 1**  The IRB is not composed of at least five members with varying backgrounds to promote complete and adequate review of research activities commonly conducted by the institution.  **Specifically, Essex IRB failed to demonstrate the ability to ascertain acceptability of the proposed research in terms of regulations, applicable law and standards of professional conduct and practice. For example:  **A. Essex IRB approved a proposed clinical investigation (Protocol					
Ease Institutional Review Board, Inc  This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding and observation, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding and observation, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding and observation, and the implement of plan to implement, corrective action in represent on otherwation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the address above. If you have my questions, please contact FDA at the address above. If you have my questions, please contact FDA at the address above. If you have my questions, please contact FDA at the address above. If you have my questions, please contact FDA at the address above. If you have my questions, please contact FDA at the address above. If you have my questions, please contact FDA at the address above. If you have my questions, please contact FDA at the address above. If you have my questions, please contact FDA at the address above. If you have my questions, please contact FDA at the address above. If you have my questions, please contact FDA at the address above. If you have my questions the submit this information to FDA at the address above. If you have my questions the submit this information to FDA at the address above. If you have my questions the submit this information to FDA at the address above. If you have my questions and previously approved a proposed clinical investigation (Protocol FDA at the Address above. If you have my questions, please contact FDA at the Address above. If you have my questions, please contact FDA at the address above. If yo	TO: Loretta	P. Szczepanski, RN, Essex II	B Vice Chairperson		
This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discouse the objection or action with the FDA representative(s) during the inspection of your facility. They are inspecting an observation, or lower implemented, or plan to implement, corrective action in response to an observation, you may discouse the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.  DURING AN INSPECTION OF YOUR FIRM WE OBSERVED:  OBSERVATION 1  The IRB is not composed of at least five members with varying backgrounds to promote complete and adequate review of research activities commonly conducted by the institution.  Specifically, Essex IRB failed to demonstrate the ability to ascertain acceptability of the proposed research in terms of regulations, applicable law and standards of professional conduct and practice. For example:  A. Essex IRB approved a proposed clinical investigation (Protocol to be conducted by a fictitious clinical investigator to be conducted by a fictitious clinical investigator to be conducted by a fictitious clinical investigator to be conducted by a fictitious investigator to be conducted by a fictitious representative to the first part of the proposed protocol was studying an investigational drug to the first part of the proposed protocol was studying an investigational drug to the first part of the proposed protocol was studying an investigational drug to the previously approved product that had been withdrawn from the market in 2004 because of an increased risk of heart attacks and strokes with long term use.  Jamet Donnelly, Investigator		tional Review Board, Inc			
This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination reparding your compliance. If you have an objection reparding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the TDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.  **DURING AN INSPECTION OF YOUR FIRM WE OBSERVED:**  **OBSERVATION 1**  The IRB is not composed of at least five members with varying backgrounds to promote complete and adequate review of research activities commonly conducted by the institution.  **Specifically, Essex IRB failed to demonstrate the ability to ascertain acceptability of the proposed research in terms of regulations, applicable law and standards of professional conduct and practice. For example:  **A. Essex IRB approved a proposed clinical investigation (Protocol to be conducted by a fictitious clinical investigator to be conducted by the sponsor conducted by a prov	CITY, STATE, ZIP CODE, COUNT	RY			
observations, and do not represent a final Agency determination reparding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, or may observation, or may one action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.  **DURING AN INSPECTION OF YOUR FIRM WE OBSERVED:**  **OBSERVATION 1**  The IRB is not composed of at least five members with varying backgrounds to promote complete and adequate review of research activities commonly conducted by the institution.  Specifically, Essex IRB failed to demonstrate the ability to ascertain acceptability of the proposed research in terms of regulations, applicable law and standards of professional conduct and practice. For example:  A. Essex IRB approved a proposed clinical investigation (Protocolate) to be conducted by a fictitious clinical investigator to be conducted by a fiction of the initial review, the IRB failed to:  1. Verify that this Clinical Investigator to be conducted by another company approved product that had been withdrawn from the market in 2004 because of an increased risk of heart attacks and strokes with long term use.  4. Assess the potential for cardiovascular risk with the use of the drug when this class of drug is known to exhibit increased risk of cardiovascular events.  5. Identify that IND **ID** Submitted by the sponsor company who had withdrawn the IND in 2008.  **ID** Submitted by the sponsor company who had withdrawn the IN	Lebanon, NJ	08833-2162	Institutional Review Boa	ird	
The IRB is not composed of at least five members with varying backgrounds to promote complete and adequate review of research activities commonly conducted by the institution.  Specifically, Essex IRB failed to demonstrate the ability to ascertain acceptability of the proposed research in terms of regulations, applicable law and standards of professional conduct and practice. For example:  A. Essex IRB approved a proposed clinical investigation (Protocol to be conducted by a fictitious clinical investigator to be state of the	observations, and do observation, or have action with the FDA	observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any			
The IRB is not composed of at least five members with varying backgrounds to promote complete and adequate review of research activities commonly conducted by the institution.  Specifically, Essex IRB failed to demonstrate the ability to ascertain acceptability of the proposed research in terms of regulations, applicable law and standards of professional conduct and practice. For example:  A. Essex IRB approved a proposed clinical investigation (Protocol to be conducted by a fictitious clinical investigator to be conducted by a fictitious clinical investigator the initial review, the IRB failed to:  1. Verify that this Clinical Investigator that the proposed protocol was studying an investigational drug that was a previously approved product that had been withdrawn from the market in 2004 because of an increased risk of heart attacks and strokes with long term use.  4. Assess the potential for cardiovascular risk with the use of the drug when this class of drug is known to exhibit increased risk of cardiovascular events.  5. Identify this exact study protocol (Protoco is known to exhibit increased risk of cardiovascular events.  5. Identify this exact study protocol (Protoco is known to exhibit increased risk of cardiovascular events.  5. Identify this exact study protocol (Protoco is known to exhibit increased risk of cardiovascular events.  5. Identify this exact study protocol (Protoco is known to exhibit increased risk of cardiovascular events.  5. Identify this exact study protocol (Protoco is known to exhibit increased risk of cardiovascular events.  6. Identify this exact study protocol (Protoco is known to exhibit increased risk of cardiovascular events.  6. Identify this exact study protocol (Protoco is known to exhibit increased risk of cardiovascular events.  6. Identify this exact study protocol (Protoco is known to exhibit increased risk of cardiovascular events.  6. Identify	DURING AN INSPEC	TION OF YOUR FIRM WE OBSERVED:			
Specifically, Essex IRB failed to demonstrate the ability to ascertain acceptability of the proposed research in terms of regulations, applicable law and standards of professional conduct and practice. For example:  A. Essex IRB approved a proposed clinical investigation (Protocol to be conducted by a fictitious clinical investigator to be conducted by the same name, street address, city and state as the fictitous investigator to conducted by an investigational drug that was a previously approved product that had been withdrawn from the market in 2004 because of an increased risk of heart attacks and strokes with long term use.  4. Assess the potential for cardiovascular risk with the use of the drug when this class of drug is known to exhibit increased risk of cardiovascular events.  5. Identify this exact study protocol (Protoco to be conducted by the sponsor company who had withdrawn the IND in 2008.   SEE REVERSE OF THIS PAGE  Dawn L. Wydner, Investigator to the protocol of the	OBSERVATION	1			
Specifically, Essex IRB failed to demonstrate the ability to ascertain acceptability of the proposed research in terms of regulations, applicable law and standards of professional conduct and practice. For example:  A. Essex IRB approved a proposed clinical investigation (Protocol to be conducted by a fictitious clinical investigator to be conducted by an investigator to be conducted by an investigation to be conducted by an investigational drug that was a previously approved product that had been withdrawn from the market in 2004 because of an increased risk of heart attacks and strokes with long term use.  4. Assess the potential for cardiovascular risk with the use of the drug when this class of drug is known to exhibit increased risk of cardiovascular events.  5. Identify this exact study protocol (Protoco to be belonged to another company who had withdrawn the IND in 2008.  SEE REVERSE OF THIS PAGE  SEE REVERSE OF THIS PAGE  Dawn L. Wydner, Investigator that IND to an increased Dawn L. Wydner, Investigator that IND the IND to an increased Dawn L. Wydner, Investigator that IND the IND that IND that IND the IND that IND the IND that IND the IND that IND that IND the IND that IND that IND that IND the IND that IND			ng backgrounds to promote complete	and adequate review of	
A. Essex IRB approved a proposed clinical investigation (Protocol to be conducted by a fictitious clinical investigator to be conducted by a fictitious clinical investigator the initial review, the IRB failed to:  1. Verify that this Clinical Investigator that the Clinical Investigator that the Clinical Investigator that the Clinical Investigator that the city and state as the fictitous investigator that the proposed protocol was studying an investigational drug that was a previously approved product that had been withdrawn from the market in 2004 because of an increased risk of heart attacks and strokes with long term use.  4. Assess the potential for cardiovascular risk with the use of the drug when this class of drug is known to exhibit increased risk of cardiovascular events.  5. Identify that IND this exact study protocol (Protoco that had been previously completed by another company who had withdrawn the IND in 2008.  SEE REVERSE OF THIS PAGE  SEE REVERSE OF THIS PAGE  The proposed clinical investigator that a fictitious sponsor to belonged to another company of the page of the company of the page of the company of the page of the company who had withdrawn the IND in 2008.  SEE REVERSE OF THIS PAGE  SEE REVERSE OF THIS PAGE  The proposed clinical investigator that a fictitious sponsor that the proposed conducted investigator that the proposed conducted investigator that the proposed conducted in 2004 because of an increased risk of cardiovascular events.  SEE REVERSE OF THIS PAGE  SEE REVERSE OF THIS PAGE  The proposed clinical investigator that the proposed conducted investigator that the proposed conducted investigator that the proposed conducted in 2004 because of an increased risk of cardiovascular events.  SEE REVERSE OF THIS PAGE  The proposed clinical investigator that the proposed conducted inves	1030anon aon vidos	commonly conducted by the hightenest.			
A. Essex IRB approved a proposed clinical investigation (Protocol to be conducted by a fictitious clinical investigator to be conducted by the same name, street address, city and state as the fictitous investigator to be conducted in 2009.  3. Identify that the proposed protocol was studying an investigational drug that was a previously approved product that had been withdrawn from the market in 2004 because of an increased risk of heart attacks and strokes with long term use.  4. Assess the potential for cardiovascular risk with the use of the drug when this class of drug is known to exhibit increased risk of cardiovascular events.  5. Identify that IND tisk swatched by the sponsor company  6. Identify that IND to submitted by the sponsor company who had withdrawn the IND in 2008.  SEE REVERSE OF THIS PAGE  Dawn L. Wydner, Investigator with the sum Unit to 103/21/2011  Days L. Wydner, Investigator with the sum Unit to 103/21/2011	research in terms of regulations, applicable law and standards of professional conduct and practice. For				
1. Verify that this Clinical Investigator  state of  2. Recognize that the Clinical Investigator  in 2009.  3. Identify that the proposed protocol was studying an investigational drug conducted in 2009.  4. Assess the potential for cardiovascular risk with the use of the drug when this class of drug is known to exhibit increased risk of cardiovascular events.  5. Identify this exact study protocol (Protocol had been previously completed by another company  6. Identify that IND submitted by the sponsor company who had withdrawn the IND in 2008.  SEE REVERSE OF THIS PAGE  Denise M. Visco, Investigator Mark Unit (DIG)  Denise M. Visco, Investigator (DIG)  Denis	to be conducted by a fictitious clinical investigator (b) (d) (d) (e) (1) (ii)				
2. Recognize that the Clinical Investigator (1964)  2. Recognize that the Clinical Investigator (1964)  3. Identify that the proposed protocol was studying an investigational drug (1964)  4. Assess the potential for cardiovascular risk with long term use.  4. Assess the potential for cardiovascular risk with the use of the drug when this class of drug is known to exhibit increased risk of cardiovascular events.  5. Identify this exact study protocol (Protocol (1964))  6. Identify that IND (1964)  6. Identify that IND (1964)  6. Submitted by the sponsor company who had withdrawn the IND in 2008.  SEE REVERSE OF THIS PAGE  6. OF THIS PAGE  Denise M. Visco, Investigator (1964)		(D) (4)			
2. Recognize that the Clinical Investigator city and state as the fictitous investigator in 2009.  3. Identify that the proposed protocol was studying an investigational drug previously approved product that had been withdrawn from the market in 2004 because of an increased risk of heart attacks and strokes with long term use.  4. Assess the potential for cardiovascular risk with the use of the drug when this class of drug is known to exhibit increased risk of cardiovascular events.  5. Identify this exact study protocol (Protocol			neid a vand me	dicai license in the	
3. Identify that the proposed protocol was studying an investigational drug previously approved product that had been withdrawn from the market in 2004 because of an increased risk of heart attacks and strokes with long term use.  4. Assess the potential for cardiovascular risk with the use of the drug when this class of drug is known to exhibit increased risk of cardiovascular events.  5. Identify this exact study protocol (Protocol had been previously completed by another company  6. Identify that IND submitted by the sponsor belonged to another company who had withdrawn the IND in 2008.  SEE REVERSE Dawn L. Wydner, Investigator Mark formally Denise M. Visco, Investigator Mark formally (03/21/2011)	2. Recognize that the Clinical Investigator ( had the same name, street address, city and state as the fictitous investigator ( conducted  cond				
increased risk of heart attacks and strokes with long term use.  4. Assess the potential for cardiovascular risk with the use of the drug when this class of drug is known to exhibit increased risk of cardiovascular events.  5. Identify this exact study protocol (Protoco had been previously completed by another company  6. Identify that IND submitted by the sponsor company who had withdrawn the IND in 2008.  SEE REVERSE Dawn L. Wydner, Investigator Mast Robinsold Denise M. Visco, Investigator M. Denise M. Denise M. Visco, Investigator M. Denise M. D	3. Identify that the proposed protocol was studying an investigational drug				
is known to exhibit increased risk of cardiovascular events.  5. Identify this exact study protocol (Protoco had been previously completed by another company  6. Identify that IND ((b) (d) submitted by the sponsor company who had withdrawn the IND in 2008.    SEE REVERSE   Dawn L. Wydner, Investigator   Dawn					
5. Identify this exact study protocol (Protoco had been previously completed by another company 6. Identify that IND submitted by the sponsor company who had withdrawn the IND in 2008.  SEE REVERSE Dawn L. Wydner, Investigator Must Company  Denise M. Visco, Investigator Must Company  D	4. Assess the potential for cardiovascular risk with the use of the drug when this class of drug				
6. Identify that IND (a) submitted by the sponsor company who had withdrawn the IND in 2008.  SEE REVERSE OF THIS PAGE  Dawn L. Wydner, Investigator Must Company  Dayretssued  Dayretssued  03/21/2011	is known to exhibit increased risk of cardiovascular events.				
6. Identify that IND (a) submitted by the sponsor company who had withdrawn the IND in 2008.  SEE REVERSE Dawn L. Wydner, Investigator Must Council Days (3)/21/2011  Denise M. Visco, Investigator Musi Uni	3. Identify this exact study protocol (Frotocol and January) had been previously completed by another				
SEE REVERSE OF THIS PAGE  SIDERITY that IND submitted by the sponsor belonged to another company who had withdrawn the IND in 2008.  BAYEISSUED  DAYEISSUED  DAYEISSUED  DAYEISSUED  03/21/2011					
SEE REVERSE OF THIS PAGE  Dawn L. Wydner, Investigator Application of the Common of th	6. Identify that IND submitted by the sponsor submitted by the sponsor belonged to another				
SEE REVERSE Janet Donnelly, Investigator Just Council Denise M. Visco, Investigator New Usi	company				
OF THIS PAGE Janet Donnelly, Investigator Must Lethnelly Denise M. Visco, Investigator New Uni			- DOLLOW I . OI . DINC	DATE ISSUED	
OF THIS PAGE Denise M. Visco, Investigator New Usin	SEE REVERSE	Janet Donnelly, Investigato	Quet Doundes		
FORM FOR 491/00/00 PROTON ORIGINAL INCOMPLETIONS INCOMPLETIONS		Denise M. Visco, Investigat	ord Deni Ihmi	03/21/2011	
	BODIN ENT 100 WOW	TAICH)	CTIONAL OBSEDUATIONS		

PAGE 1 OF 4 PAGES

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION			
DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION		
10 Waterview Blvd., 3rd Floor	03/14/2011 ~ 03/21/2011		
Parsippany, NJ 07054	FEINUMBER		
(973) 331-4900 Fax: (973) 331-4969	2246448		
Industry Information: www.fda.gov/oc/indu	stry		
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED			
TO: Loretta P. Szczepanski, RN, Essex IRB Vice Chairperson			
FIRM NAME	STREET ADDRESS		
Essex Institutional Review Board, Inc	121 Main St		
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED		
Lebanon, NJ 08833-2162	Institutional Review Board		

B. Essex IRB reviewed a Phase I (first in man) investigational vaccine study.

Protocol (1976), and incorrectly determined that the research was no more than minimal risk to subjects.

C. Essex IRB reviewed Protocol # for an anti-viral, and failed to include known side effects (acute renal failure in elderly patients) provided in the Package insert into the IRB approved consent form. In addition, the IRB removed a known adverse event (graft rejection) from the original sponsor provided ICF with no documented rationale.

#### **OBSERVATION 2**

The IRB approved the conduct of research, but did not determine that risks to subjects were minimized by using procedures which were consistent with sound research design and which did not unnecessarily expose subjects to risk.

Specifically, one of the criteria for IRB approval is that the IRB determine that risks to subjects are minimized. Essex IRB's process for assessment of risk in proposed research is inadequate.

The regulations at 21 CFR 56.102(i) define minimal risk as "The probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests." Essex IRB's application of this definition to proposed research routinely fails to consider the type of test article, the investigational nature of the test article, and its use in the proposed research.

For example,

The IRB incorrectly determined that the two (2) following studies, which involve the use of an investigational drug or vaccine respectively, were no more than minimal risk:

1.	(b) (4)	
SEE REVERSE OF THIS PAGE		03/21/2011
FORM FDA 483 (09/09)	PREVIOUS POUTION ORSOLETE INSPECTIONAL ORSERVATIONS	PAGE 2 OF A PAGES

	DEPARTMENT OF HEAL	TH AND HUMAN S G ADMINISTRATION	ERVICES	
DISTRICT ADDRESS AND PHONE	NUMBER	O ADMINISTRATION	DATE(S) OF INSPECTION	
10 Waterview Blvd., 3rd Floor			03/14/2011 - 03/21/	2011
Parsippany, No. (973) 331-490			2246448	
	rmation: www.fda.gov/oc/indu	stry		
	rowwomreporrissueb P. Szczepanski, RN, Essex IF		person	
FIRM NAME		STREET ADDRESS		
Essex Institu	tional Review Board, Inc	121 Main St		
	 08833-2162	Institution	al Review Board	
		(b) (4)		
2.				
OBSERVATION: The IRB does not reinformed consent.	gquire that information given to subjects a	s part of informed	consent contain all necessary	elements of
intormed consent.				
	Freview does not ensure safety of a ure subjects are fully educated on t			
A. For clinicontrol potential included	for cardiovascular risk with the us  (b)(d)  is known to exhibite.		•	
into the	B reviewed (b) (d)  known side effects (acute renal fails  RB approved consent form. In add  ) from the original sponsor provide	are in elderly partition, the IRB r		ackage insert
OBSERVATION	4			
	termine at the time of initial review that a ards for Children in Clinical Investigation		pliance with 21 CFR Part 50 S	ubpart D,
	2 out of 2 Pediatric studies review of the pediatric risk category assign			IRB.
	EMPLOYEE(S) SKRATURE	(000.)		DATE ISSUED
SEE REVERSE OF THIS PAGE	Dawn L. Wydner, Investigato Janet Donnelly, Investigato Denise M. Visco, Investigat	r Octob		03/21/2011

INSPECTIONAL OBSERVATIONS

PAGE 3 OF 4 PAGES

FORM FDA 483 (09/08)

PREVIOUS EDITION OBSCLETE

DEPARTMENT OF HEALTH AND HUMAN SERVICES				
	SY ADDRESS AND PHONE NUMBER FOOD AND DRUG ADMINISTRATION		DATE(S) OF INSPECTION	
10 Waterview Parsippany, N	Blvd., 3rd Floor J 07054		03/14/2011 - 03/21/ FEI NUMBER	/2011
(973) 331-490	0 Fax: (973) 331-4969		2246448	
Industry Info	rmation: www.fda.gov/oc/indu	stry		
TO: Loretta	P. Szczepanski, RN, Essex II	RB Vice Chair	rperson	
Essex Institu	tional Review Board, Inc	121 Main St		
	08833-2162	Institution	al Review Board	
OBSERVATION	5 (23)			
	etings have not been prepared in sufficien controverted issues and their resolution.	t detail to show ac	ctions taken by the IRB and a	written summary
	nutes of IRB meetings have not been non-significant vs. significant devi			
OBSERVATION 6  The IRB did not follow written procedures for ensuring prompt reporting to appropriate institutional officials and the FDA of any suspension or termination of IRB approval.  Specifically, SOP SX-SOP-20-6-1/3, "Suspension or Termination of Apprval of Research" requires the				
IRB to suspend or terminate its approval of a research study if there is evidence of ethical or scientific misconduct. Essex IRB became aware on February 7, 2011, that the study to be conducted by was fictitious, however to date, the IRB failed to terminate its approval in accordance with their SOP.				
				•
i				
	EMPLOYEE(S) SIGNATURE		^	DATE ISSUED
SEE REVERSE OF THIS PAGE	Dawn L. Wydner, Investigate Janet Donnelly, Investigate Denise M. Visco, Investigat	ratellog r gant le or Neni- l	Winder Vini	03/21/2011
	<u> </u>			



# Essex Institutional Review Board, Inc.

121 Main Street • Lebanon, New Jersey 08833 Telephone (908) 236-7735 • Fax (908) 236-2027 www.essexirb.com

April 11, 2011

Douglas I. Ellsworth District Director HFR-CE300 New Jersey District (NWJ-DO) 10 Waterview Blvd., 3rd Floor Parsippany, NJ 07054

Dear Mr. Ellsworth:

Reference is made to the inspection by the Food and Drug Administration inspectors, LCDR. Dawn Wydner, USPHS, Janet C. Donnelly, RAC, and Denise Visco, PhD, at our facility located at 121 Main Street, Lebanon, NJ 08833, on March 14 -21, 2011. This correspondence addresses the six observations delineated in the resulting Form FDA 483 presented after the inspection. Each observation (in bold) is listed below followed by our response and corrective actions.


Essex Institutional Review Board, Inc. ("Essex IRB") is committed to ensuring the protection of human subjects involved in clinical research and as such takes all FDA observations very seriously. In light of the unusual events associated with this inspection, Essex IRB has undertaken a complete review of its standard operating practices and procedures to ensure compliance with all applicable FDA laws and regulations. To that end, Essex IRB is in the process of engaging a consultant that can assist the firm with the evaluation of its IRB review process. Because Essex IRB recognizes the seriousness of the issues raised by the FDA, the firm has begun the review of the operating practices and procedures and retraining of Board members and staff.

## Observation 1:

The IRB is not composed of at least five members with varying backgrounds to promote complete and adequate review of research activities commonly conducted by the institution. Specifically, Essex IRB failed to demonstrate the ability to ascertain acceptability of the proposed research in terms of regulations, applicable law and standards of professional conduct and practice. For example:

Before addressing each item identified in this Observation, Essex IRB believes it is important to address the larger question concerning the composition of its Board. Essex IRB believe that its IRB is duly constituted with the necessary scientific and non-scientific expertise to provide adequate and complete review of the studies it commonly reviews. However, the firm recognized that procedural changes and additional training of its Board members and staff must be implemented in order to provide the Board with the information necessary to conduct its review function. The procedural changes and training that Essex IRB has adopted, or will be adopting are described below.





Under Observation 1.A, the FDA points to six items that Essex did not identify during its initial review of the fictitious study. Essex IRB's procedures were set up to review clinical research, not to detect fabricated submissions such as those submitted by the bogus company. However, Essex IRB recognizes that this fabricated submission raises questions about the robustness of its review process as it relates to legitimate study submissions, and thus, the firm is taking steps to revise its study intake procedures to address this concern.

company who had withdrawn the IND in 2008.

Items 1 and 2 concern a failure to verify the qualifications of the clinical investigator. According to FDA's regulations, it is the sponsor's responsibility to select "qualified investigators" pursuant to 21 CFR § 312.50 and 21 CFR § 812.40. Thus, consistent with the regulations and Essex IRB's procedures, the firm relied on the medical licensure information provided by the fictitious sponsor, along with additional information about the non-existent principal investigator provided in the Essex IRB Site Application Letter (SAL), to confirm the clinical investigator's qualifications. However, going forward, Essex IRB has implemented procedures to verify the medical license documents submitted for all principal investigators as part of its review process. The medical license verification process will require Essex to check the submitted license against authoritative sources such as the specific board of medical examiners identified as issuing the license to the principal investigator. This step will eliminate attempts to submit a study that includes a fictitious clinical investigator, but it will also benefit the review process by adding an additional check on the information submitted by real sponsors and investigators. The IRB administrators and Board members will be trained on the revised SOP.

Items 3 and 4 involve a failure to identify risks associated with the study agent. As part of the study submission to Essex IRB, the firm requires sponsors and investigators to submit the study protocol and investigator brochure or investigational plan, if applicable, to the IRB for review. Where an Investigational New Drug ("IND") or Investigational Device Exemption ("IDE") is required these documents must contain, under 21 CFR § 312.23 or 21 CFR § 812.25, among other things, a summary of all safety and efficacy information concerning the study agent, including bibliographies of all published literature. In hindsight, it is now clear that the documents submitted by the fictitious sponsor were intentionally inadequate in describing risk information, including cardiovascular risks. While the study in this case was fictitious, Essex IRB recognizes the need to impose additional requirements on sponsors and investigators to assure that such documents are complete.

As part of its site review process, Essex IRB also checks the principal investigator's name against FDA Warning Letters, Form FDA 483s, and the disqualification and debarment lists maintained of <a href="www.fda.gov">www.fda.gov</a>. In addition, Essex IRB maintains a list of clinical investigators that have reported receipt of Form FDA 483s and/or FDA Warning Letters while under the firm's oversight.



**=** 

Therefore, going forward, sponsors and investigators will be required to attest to the completeness and accuracy of study submissions consistent with regulatory requirements.

Further, the Board will undertake additional measures to assess the completeness of the study information submitted by referring to authoritative sources, such as PubMed, for a review of the available published literature related to or concerning the study agent. Essex IRB is revising its SOP "Criteria for Approval of Research" to adopt this requirement, and IRB administrators will be trained on conducting such reviews.

Items 5 and 6 above cite Essex IRB for not recognizing the previously completed by another company, and for failure to identify the IND number as belonging to another company who had withdrawn the IND in 2008. As the FDA knows, the FDA does not make public the IND number assigned to a particular drug study during the investigational stage of drug development due to sponsor confidentiality considerations. Further, despite the IRB's role in the review process of these studies, the FDA does not provide IRBs with access to the IND number so that the IRB can validate the number submitted by the sponsor or investigator. Thus, while Essex IRB recognizes that it was deceived by this fictitious sponsor in this particular case, and that in this rare case the IND number was publicly available; the firm does not believe that regular internet checks of IND numbers will serve a purpose useful to the IRB review process. Nevertheless, going forward, sponsors and investigators will be required to attest to the accuracy of the study information submitted to Essex IRB.

B. Essex IRB reviewed a Phase I (first in man) investigational risk to subjects.

This item addresses Essex IRB's process for undertaking risk determinations. Because this matter is also addressed in connection with Observation 2, Essex IRB addresses this item in its response to Observation 2.

C. Essex IRB reviewed in elderly patients) provided in the Package insert into the IRB approved consent form. In addition, the IRB removed a known adverse event (graft rejection) from the original sponsor provided ICF with no documented rationale.

Essex IRB agrees that the known side effect provided in the package insert should have been included as part of the informed consent form. As a result, Essex will be reviewing and revising its "Informed Consent Checklist" to assess, among other things, that risk information in the Informed Consent document is consistent with risk information identified in the protocol, investigator brochure, or other relevant document (e.g., package insert), and to request information from the sponsor or investigator where inconsistencies are identified. Essex IRB administrators and Board members will be trained on the revised procedures.

With regard to the known adverse event that was removed from the informed consent form, Essex IRB inadvertently failed to document the reason for the removal of the adverse event. After reviewing the information on this adverse event with the Board, Essex IRB determined that it should have been removed from one paragraph and moved to another paragraph. The information was inadvertently removed and not moved to the new paragraph. However, going forward, Essex IRB will assure that such information is documented in the IRB meeting. In its responses to Observation 4 below, Essex discusses new procedures and training as it relates to good meeting minutes practices.





4/11/2011


#### Observation 2:

The IRB approved the conduct of research, but did not determine that the risks to subjects were minimized by using procedures which were consistent with sound research design and which did not unnecessarily expose subjects to risk. Specifically, one of the criteria for IRB approval is that the IRB determine that the risks to subjects are minimized. Essex IRB's process for assessment of risk in proposed research is inadequate.

The regulations at 21 CFR 56.102(i) define minimal risk as "The probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests." Essex IRB's application of this definition to proposed research routinely fails to consider the type of test article, the investigational nature of the test article, and its use in the proposed research.

## For example,

The IRB incorrectly determined that the two (2) following studies, which involve the use of an investigational drug or vaccine respectively, were no more than minimal risk:



Essex IRB agrees that it incorrectly identified the studies mentioned above as presenting no more than minimal risk to subjects. Despite the minimal risk decision the studies were still subject to full board review. As a result, Essex IRB is revising its SOPs to assist the Board when making risk determinations. As noted by FDA, 21 CFR 56.102(i) defines minimal risk to mean

[t]he probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or test.

All determinations about the degree of risk presented by a study will be made in accordance with the regulatory definition of minimal risk. All Essex Board members and administrators will be provided training on the revised SOP, with an emphasis on the meaning of minimal risk.



This Observation raises the same issues with regard to the informed consent document presented under Observations 1.A.3 and 4, and 1C. A summary of the corrective actions that will be implemented by Essex IRB are described below, but please see the firm's response to Observation 1 for a complete discussion of the corrective actions that will be adopted by Essex IRB in response to the issues raised by the FDA.

In summary, in order to assure that Essex IRB has information sufficient to conduct its review function and assure completeness of the informed consent document, sponsors and investigators must attest to the completeness and accuracy of the study submission consistent with regulatory requirements. The Board will also undertake additional measures to assess the completeness of the study information submitted by referring to authoritative sources for a review of available published literature related to or concerning the study agent.

Further, Essex is revising its Informed Consent Checklist to require review of the risk information in the Informed Consent document to assure it is consistent with the risk information identified in the protocol,



investigator brochure, or other relevant document, and to request information from the sponsor or investigator where inconsistencies are identified.

IRB administrators and Board members training associated with these procedural changes is described in Essex IRB's response to Observation 1.

## **Observation 4:**

The IRB did not determine at the time of initial review that a study was in compliance with 21 CFR Part 50 Subpart D, "Additional Safeguards for Children in Clinical Investigations." Specifically, for 2 out of 2 Pediatric studies reviewed, Essex IRB failed to document and provide communication of the pediatric risk category assigned to the research as determined by the IRB.

Essex IRB has in place an SOP governing the assessment of degree of pediatric risk in accordance with 21 CFR Part 50, Subpart D. Essex IRB failed to document its pediatric risk determination for these two studies. As a result of this Observation, Essex IRB will be retraining its IRB administrators and Board members on the need to document in the meeting minutes the risk determination, along with other required documentation depending on the identified risk determination.



In addition, Essex IRB is developing an SOP describing how to prepare good meeting minutes. Essex IRB employees will be trained on this SOP, which explains how to summarize the details gathered during the Board meeting, how to incorporate those details into the meeting minutes to ensure that comprehensive meeting minutes are prepared in a timely fashion, and the elements that must be included in the meeting minutes. The training will be conducted when the SOP review is complete.



Finally, Essex is in the process of auditing all ongoing pediatric studies subject to Essex IRB review to assure that the risk determination has been appropriately documented.

### Observation 5:

Minutes of IRB meetings have not been prepared in sufficient detail to show actions taken by the IRB and a written summary of the discussion of controverted issues and their resolutions. Specifically, minutes of IRB meetings have not been prepared in sufficient detail to show pediatric risk determinations, non-significant vs. significant device determinations, and controverted issues and their resolution.

This Observation raised issues similar to those raised as Observations 4. As stated in our response to Observation 4, an SOP is being developed and staff will be trained on good meeting minutes and practices. Among other things, the SOP includes the requirement to document pediatric risk determinations, non-significant v. significant device determinations, and the discussion of controverted issues.

#### Observation 6:

The IRB did not follow written procedures for ensuring prompt reporting to appropriate institutional officials and the FDA of any suspension or termination of IRB approval. Specifically, SOP SX-SOP-20-6-1/3, "Suspension or Termination of Approval of Research" requires the IRB to suspend or terminate its approval of a research study if there is evidence of ethical or scientific misconduct. Essex IRB became aware on February 7, 2011, that the study to be conducted by was fictitious, however to date, the IRB failed to terminate its approval in accordance with their SOP.

As the FDA knows, Essex IRB notified the FDA about the fictitious study on February 8, 2011. While Essex IRB took the necessary measures to notify the FDA about the fraudulent study submission, it failed to recognize the need to internally terminate its approval of a fraudulent study. After being so informed during the FDA inspection of our facility, Essex IRB immediately terminated its approval of the fictitious



study. Because the mechanism for such action for a legitimate study is already established in our SOPs, Essex is confident that it would follow the appropriate procedures in the future.

\*\*\*\*\*

We appreciate the professional conduct and thoroughness of Lieutenant Commander Wydner, Ms. Donnelly and Dr. Visco during the inspection. Their observations, recommendations and information shared with us are taken very seriously and shall be adhered to as Essex resumes its function as an Independent IRB. As noted above, we have begun the process of revising our SOPs and retraining of the Board and staff. We will be updating FDA on our actions.

Respectfully,

Glenn P. Lambert, MD

Chairman

Cc.: Andrea Slavin, Consumer Safety Officer, CDER

Silver Spring, MD 20993

Gem P. Lambert, us

